Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Taochen He

Matched on ORCID iD 0009-0000-0655-4547; OpenAlex author ID A5048735941. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2024: 1 paper · 2025: 3 papers · 2026: 5 papers

Papers 9

  1. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
  2. DDR1 sustains ferroptosis resistance in pancreatic ductal adenocarcinoma via SLC40A1-mediated iron homeostasis. Co-author DOI 10.1038/s41388-026-03980-w↗
  3. Supervising the recurrence of pancreatic ductal adenocarcinoma using CtDNA-based MIR129-2 methylation detection. Co-author DOI 10.1097/js9.0000000000003449↗
  4. RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. Co-author DOI 10.1158/0008-5472.can-26-0333↗
  5. Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications. Co-author DOI 10.20892/j.issn.2095-3941.2025.0650↗
  6. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  7. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  8. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  9. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. Co-author DOI 10.1136/jitc-2023-008694↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ning Pu · 8 shared papers, 2024–2026 · strength 1.73
  2. Wenhui Lou · 8 shared papers, 2024–2026 · strength 1.72
  3. Hanlin Yin · 7 shared papers, 2024–2026 · strength 1.49
  4. Qiangda Chen · 6 shared papers, 2024–2026 · strength 1.23
  5. Yun Jin · 4 shared papers, 2025–2026 · strength 0.83
  6. Wenchuan Wu · 4 shared papers, 2024–2026 · strength 0.82
  7. Wenquan Wang · 3 shared papers, 2025–2026 · strength 0.68
  8. Zhihang Xu · 3 shared papers, 2025–2026 · strength 0.66
  9. Jun Yu · 3 shared papers, 2025–2026 · strength 0.63
  10. Jiande Han · 3 shared papers, 2024–2025 · strength 0.60
  11. Liang Liu · 2 shared papers, 2026 · strength 0.46
  12. Yanfei An · 2 shared papers, 2025–2026 · strength 0.42
  13. Yaolin Xu · 2 shared papers, 2025 · strength 0.41
  14. Haibo Wang · 2 shared papers, 2025 · strength 0.41
  15. Joseph R. Habib · 2 shared papers, 2024–2025 · strength 0.38
  16. Chuxiong Cheng · 1 shared paper, 2026 · strength 0.26
  17. Liang Liu · 1 shared paper, 2026 · strength 0.26
  18. Liang Liu · 1 shared paper, 2026 · strength 0.24
  19. Huijuan Li · 1 shared paper, 2026 · strength 0.24
  20. Chao Song · 1 shared paper, 2026 · strength 0.23
  21. Chaoyu Pang · 1 shared paper, 2026 · strength 0.23
  22. Haibo Wang · 1 shared paper, 2026 · strength 0.23
  23. Yifei Zhang · 1 shared paper, 2026 · strength 0.23
  24. Yazhou Wang · 1 shared paper, 2026 · strength 0.23
  25. Yanfei An · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.